Podcast Episodes
Back to Search
On a visit through London today, NodThera's CEO Dan Swisher discusses the company's brain-penetrant NLRP3 platform, including an asset that's in phase 2 for weight loss
He discusses the science behind NLRP3, and describes why he thinks NodThera's brain penetration differentiates it from other programs from pharma and…
1 year, 1 month ago
Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline
He describes the benefits of prime editing, walks us through human proof-of-concept data that was announced in a patient with Chronic Granulomatous D…
1 year, 1 month ago
Kailera Therapeutics' partner Hengrui announced positive p3 results for its GLP1/GIP agonist in China - biotech veteran and Kailera CEO Ron Renaud walks us through the company's obesity space strategy
He describes why Kailera chose to in-license a GLP1/GIP specifically, and describes where he sees this asset placing in the competitive landscape bas…
1 year, 2 months ago
Southampton professor, and Curve Therapeutics' CSO, Ali Tavassoli describes the unique properties of cyclic peptides and why he believes Curve's cell-based method to drug discovery makes it different
He describes the properties that make cyclic peptides unique compared to small molecules and antibodies, and how Curve's approach is different than o…
1 year, 2 months ago
Southampton, UK based Curve Therapeutics believes its mammalian cell-based 'Microcycle' platform is a better way to do drug discovery - lead programs from it target HIF-1/HIF-2 and ATIC
Co-Founder and CEO Simon Kerry discusses being in Southampton, and why he belives the 'Microcycle' platform beats screening in traditional well plate…
1 year, 2 months ago
Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)
Jorge Santos da Silva walks us through the scientific design of the molecule, which is a nanobody that binds to IL-17A, IL-17F, and albumin. He compa…
1 year, 2 months ago
KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks
Ben Palleiko is asked about the company's take on headlines that were in the news during the FDA review of the drug, and he describes the need for an…
1 year, 2 months ago
AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery
Co-Founder & CEO Peter Fedichev describes why he believes reading the amino acid sequences that have been written into the human genome over time is …
1 year, 2 months ago
Jones Research analyst Catherine Novack discusses Capricor's regulatory roller coaster, RNA editing, and more
She gives a scenario analysis in the event that FDA asked Capricor for more data rather than approving the therapy by its August 31st decision date. …
1 year, 2 months ago
ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features
He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same place. Plus, wri…
1 year, 2 months ago